Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Globe Newswire•08/11/2026•10:00 ET
3
Key Highlights
- ➤100% (6/6) dermatomyositis patients maintained immunomodulator-free TIS responses through one year
- ➤100% (5/5) biopsied lupus nephritis patients achieved immunomodulator-free DORIS remission
- ➤71% (5/7) systemic sclerosis patients achieved rCRISS-50 at one year
- ➤Systemic sclerosis ILD patients recorded 9% mean FVC improvement at one year
- ➤71-patient experience showed 94% had no or Grade 1 CRS; no IEC-HS reported
Expert Statements
David J. Chang, M.D., Chief Medical Officer of Cabaletta
“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile”
David J. Chang, M.D., Chief Medical Officer of Cabaletta
“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”
100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids
100% (5 of 5) of lupus nephritis patients with follow-up from six months to two years achieved immunomodulator-free DORIS remission and evidence of little-to-no disease activity based on repeat kidney biopsies
Get started
Create a free account to read the full story.